Alkermes (ALKS) EVP R&D Craig Hopkinson trades 9,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported option exercises and share sales in Alkermes ordinary shares. On February 2, 2026, he exercised an employee stock option for 5,000 shares at an exercise price of $19.34, converting it into ordinary shares. The filing shows two same-day sales of ordinary shares: 5,000 shares sold at a weighted average price of $34.2449 and 4,000 shares sold at $33.54. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the reported trades, Hopkinson directly owns 57,740 ordinary shares and holds 26,356 employee stock options that are fully vested in accordance with their terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last) (First) (Middle)

900 WINTER ST.

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP R&D, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/02/2026		M(1)		5,000	A	$19.34	66,740	D
Ordinary Shares	02/02/2026		S(2)		5,000	D	$34.2449(3)	61,740	D
Ordinary Shares	02/02/2026		S(2)		4,000	D	$33.54	57,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$19.34	02/02/2026		M(1)			5,000	(4)	02/22/2031	Ordinary Shares	5,000	$0	26,356	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.67 to $34.64. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Alkermes (ALKS) report for Craig C. Hopkinson?

Alkermes reported that EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised 5,000 stock options and sold 9,000 ordinary shares on February 2, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025.

How many Alkermes (ALKS) shares does Craig C. Hopkinson own after the Form 4 transactions?

After the reported transactions, Craig C. Hopkinson directly owns 57,740 Alkermes ordinary shares. He also holds 26,356 employee stock options, which the filing states are fully vested according to their terms, providing additional potential exposure to Alkermes equity.

At what prices did Craig C. Hopkinson trade Alkermes (ALKS) shares on February 2, 2026?

The Form 4 shows an option exercise price of $19.34 per share for 5,000 options. It also reports sales of 5,000 shares at a weighted average price of $34.2449 and 4,000 shares at $33.54 on the same date.

Was the Alkermes (ALKS) insider trading activity under a Rule 10b5-1 plan?

Yes. The filing explains that both the option exercise and the share sales on February 2, 2026 were effected under a Rule 10b5-1 trading plan adopted by Craig C. Hopkinson on March 14, 2025, indicating pre-arranged trading instructions.

What type of derivative security did Craig C. Hopkinson exercise at Alkermes (ALKS)?

He exercised an Employee Stock Option (Right to Buy) covering 5,000 Alkermes ordinary shares at an exercise price of $19.34 per share. The filing notes these options are fully vested and shows 26,356 options remaining beneficially owned afterward.

What role does Craig C. Hopkinson hold at Alkermes (ALKS) according to the Form 4?

According to the Form 4, Craig C. Hopkinson serves as EVP R&D, Chief Medical Officer of Alkermes plc. The filing lists him as an officer of the company and reports his direct ownership of ordinary shares and employee stock options.